"This Phase I/II trial will enrol 29 patients and involve the use of Bisantrene in combination with the nucleoside analogues, clofarabine and fludarabine. Unpublished preclinical data fromProfessors Andersson and Valdez of the MD Anderson Cancer Clinic in Houston, Texas has identified strong synergistic killing of AML cells using this three-drug combination.
Human ethics approval for this trial has been granted and the first patient is expected to be treated in Q2 CY 2021. The trial is scheduled to run for up to 36 months, but Race will release progress updates on patient responses as they are received.
Trial contract details are current being finalised and Race expects to sign in early Q2 CY 2021."
I feel like I've been waiting for this trial since late last year. Its almost Q3 and definitely not early Q2. Has any unforseen issues arise?
- Forums
- ASX - By Stock
- Ann: Race Strategic Update March 2021
"This Phase I/II trial will enrol 29 patients and involve the...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.78 |
Change
-0.005(0.28%) |
Mkt cap ! $303.3M |
Open | High | Low | Value | Volume |
$1.80 | $1.84 | $1.78 | $133.8K | 73.76K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 15072 | $1.78 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.87 | 1793 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 15072 | 1.780 |
1 | 1690 | 1.775 |
1 | 11200 | 1.770 |
1 | 2200 | 1.760 |
1 | 569 | 1.755 |
Price($) | Vol. | No. |
---|---|---|
1.870 | 1793 | 1 |
1.880 | 2351 | 1 |
1.890 | 1000 | 1 |
1.895 | 7800 | 1 |
1.950 | 30264 | 5 |
Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
TON
TRITON MINERALS LTD
Adrian Costello, Executive Director
Adrian Costello
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online